STOCKS TELEGRAPH

Author: Asim Kamal

  • Here is why Cyclerion Therapeutics Inc. (CYCN) stock turnaround in the after-hours on Thursday?

    Cyclerion Therapeutics Inc. (CYCN) shares surged 15.83% in after-hours on Thursday, July 22, 2021, and closed at $4.17 per share. Earlier, CYCN’s stock lost 2.44% in the morning session, to close Thursday’s session at $3.60. CYCN shares have fallen 6.01% over the last 12 months, and they have moved up 8.76% in the past week. Over the past three months, the stock has gained 29.50%, while over the past six months, it has shed 8.11%.

    Let’s discuss its recent news and developments briefly.

    Clinical trial design presentation of CY6463 at upcoming 2021 AAIC

    On July 22, 2021, Cyclerion Therapeutics, Inc announced to present clinical trial design for a Phase 2a study of its lead development candidate, CY6463, in participants with Alzheimer’s disease with vascular pathology at the upcoming Alzheimer’s Association International Conference 2021 (AAIC). AAIC will be held July 26-30, 2021, virtually and in Denver, CO.

    What is CY6463?

    CY6463, an oral, first-in-class, central nervous system (CNS)-penetrant sGC stimulator, for neurological diseases associated with cognitive impairment, including Alzheimer’s disease with vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), as well as Cognitive Impairment Associated with Schizophrenia (CIAS) which Cyclerion is developing.

    Cyclerion Therapeutics & Beacon Biosignals  partnership

    On July 8, 2021, Cyclerion Therapeutics, Inc and Beacon Biosignals announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion’s investigational therapeutics for neurological diseases associated with cognitive impairment.

    The licensing agreement with Akebia Therapeutics

    On June 04, 2021, Cyclerion Therapeutics, Inc entered into an exclusive, global license agreement with Akebia Therapeutics, Inc for the development and commercialization of praliciguat, an oral sGC stimulator.

    The total agreement value is up to $585 million and Cyclerion is eligible to receive up to $225M in pre-commercial milestones, including up to $15M in the first 18 months.

     $18 Million Private Placement announcement

    On June 04, 2021, Cyclerion Therapeutics, Inc announced a direct private sale of approximately $18 million of Cyclerion shares of common stock to EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners, LP, Invus, Peter Hecht, Ph.D., Lincoln Park Capital Fund, LLC and Polaris Partners.

    Recent participation in the health conference

    Cyclerion Therapeutics recently participated at the Jefferies Virtual Healthcare Conference which was held on Tuesday, June 1, 2021. The company’s management presented a corporate overview of the company.

    Exceptional share purchased by Cyclerion CEO

    On May 9, 2021, the news came to the market that the CEO & Director of Cyclerion, Peter Hecht recently bought a whopping US$1.7m worth of stock, at US$2.43, boosting their holding by 309%.

    New Board member

    On April 26, 2021, Cyclerion Therapeutics, Inc appointed Errol De Souza, Ph.D., to its board of directors.

    Conclusion

    The recent announcement about the clinical trial design presentation of CY6463 at the upcoming 2021 AAIC could be the reason behind its turnaround in the after-hours on Thursday.

  • Why Acorda Therapeutics Inc. (ACOR) flipped in the after-hours on Thursday?

    Acorda Therapeutics Inc. (ACOR) shares rallied 24.67% in after-hours on Thursday, July 22, 2021, and closed the daily trading at $4.75 per share. Earlier in the morning session, ACOR’s stock went down 4.27% to close Thursday’s normal session at $3.81. ACOR shares have fallen 25.43% over the last 12 months, and they have moved down 1.80% in the past week. Over the past three months, the stock has lost 19.45%, while over the past six months, it has shed 47.23%.

    Commercialization agreement with Esteve Pharmaceuticals forINBRIJA in Spain

    On July 22, 2021, Acorda Therapeutics, Inc entered into distribution and supply agreements with Esteve Pharmaceuticals S.A (ESTEVE) to commercialize INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor. 

    ESTEVE will have exclusive distribution rights to INBRIJA in the territory and ACORDA will supply the product to ESTEVE. ESTEVE expects to launch INBRIJA in Spain in the fourth quarter of 2022. In return, ACORDA will receive a significant double-digit percentage of the selling price of INBRIJA in Spain in exchange for the supply of the product.

    Repayment of Convertible Senior Notes

    On June 15, 2021, Acorda Therapeutics, Inc repaid in full its 1.75% Convertible Senior Notes due 2021. Before their maturity and repayment, there were $69.0 million aggregate principal amount of 2021 notes outstanding. The 2021 notes were repaid using cash on hand.

    Latest financial results announcement

    On May 6, 2021, Acorda Therapeutics, Inc reported its financial results for the first quarter of 2021 which ended on March 31, 2021.

    Q1 2021 financial highlights

    • Acorda Therapeutics reported revenue of 5 million in Q1 2021, compared to $4.4 million for the same quarter in 2020.
    • Research and development expenses were $4.7 million in Q1 2021 compared to $7.7 million in Q1 2020.
    • Sales, general and administrative expenses were $34.0 million in Q1 2021 compared to $41.1 million in Q1 2020.
    • The Company suffered a GAAP net loss of $33.5 million, or $3.53 per diluted share in Q1 2021 compared to GAAP net loss of $6.5 million, or $0.81 per diluted share in Q1 2020.
    • The Company had cash, cash equivalents, short-term investments, and restricted cash of $148.4 million on March 31, 2021, compared to $102.9 million at the end of 2020.

    The financial outlook for FY 2020

    For the full year of 2021, Acorda is expecting

    • Net revenue to be in the range of $75 to $85 million.
    • Operating expenses to be in the range of $130 to $140 million.

    Conclusion

    The ACOR stock flipped in the after-hours after the company announced its recent agreement with Esteve Pharmaceuticals. It can continue its positive momentum on Friday as well.

  • Socket Mobile Inc. (SCKT) stock soared in the after-markets on Thursday but Why?

    Socket Mobile Inc. (SCKT) shares soared 79.31% in after-hours on Thursday, July 22, 2021, and closed the day at $10.40 per share. Earlier in the morning session, SCKT’s stock lost 3.01% to close Thursday’s session at $5.80 per share. SCKT shares have risen 297.26% over the last 12 months, and they have moved up 1.40% in the past week. Over the past three months, the stock has lost 21.62%, while over the past six months, it has declined 100.00%.

    Let’s see what’s happening with SCKT in the recent past?

    Financial results announcement

    On July 22, 2021, Socket Mobile, Inc released its financial results for the three and six months ended June 30, 2021.

    Q2 2021 financial highlights

    • Socket Mobile reported revenue of $6.0 millioninQ2 2021 compared with $2.7 million for the same period in 2020.
    • The gross margin was 55% in Q2 2021 compared with 50% in Q2 2020.
    • Operating income was $814,000inQ2 2021 compared to an operating loss of $810,000 in Q2 2020.
    • In Q2 2021, operating expenses were$2.4 million compared to 2.2 million for the same quarter in 2020.
    • The company earned a net income of $2.6 million in Q2 2021 compared to $0.768 million in Q2 2020.

    Built-In compatibility with EU Digital COVID Certificates

    On June 2, 2021, Socket Mobile, Inc announced that its entire family of barcode scanners offer out-of-the-box support for applications designed to facilitate EU Digital COVID Certificates.

    The Certificate will facilitate travel within EU borders by providing information such as vaccination, test and recovery status via a digitally signed QR code.

    New appointment

    On May 18, 2021, Socket Mobile, Inc appointed Dave Holmes as Chief Business Officer.

    Dave has more than 20 years of experience and have wealth of knowledge and experience that will enable Socket Mobile to navigate the complexity of the ecosystems and become a key player in these emerging markets.

    Q1 2021 financial results announcement

    On April 22, 2021, Socket Mobile, Inc released its financial results for the first quarter of 2021.

    Q1 2021 financial highlights

    • Socket Mobile generated a revenue of $4.8 million in Q1 2021 compared to $4.2 million in the first quarter of 2020.
    • Operating expenses were $2.3 million in Q1 2021 which were the same in Q1 2020.
    • The company reported a net income of $203,000, or $0.03per basic and fully diluted share in Q1 2021, compared to a net loss of ($90,000), or ($0.01) per basic and fully diluted share, in the first quarter of 2020.
    • As of March 31, 2021 company had a cash amount of $5.0 million.

    Conclusion

    The improved financial results took the SCKT stock to new heights in the after-markets on Thursday. we are pretty sure that SCKT will continue its momentum on Friday as well.

  • Why Lightspeed POS Inc. (LSPD) stock went up in the after-hours on Monday?

    Why Lightspeed POS Inc. (LSPD) stock went up in the after-hours on Monday?

    Lightspeed POS Inc. (LSPD) shares gained 10.80% in after-hours on Monday, July 19, 2021, and closed at $86.00. Earlier in the morning session, LSPD’s stock lost 0.86% to close Monday’s morning session at $77.62. The stock volume remained 0.64 million shares, which was lower than the average daily volume of 0.85 million shares within the past 50 days. LSPD shares have risen 212.74% over the last 12 months, and they have moved down 7.84% in the past week. Over the past three months, the stock has gained 20.36%, while over the past six months, it has lost 10.43%.

    Let’s have a look at its recent news and development.

    COVID-19 Impact on North American LGBTQ+ Businesses

    On July 12, 2021, Lightspeed announced the results of a study on the impacts of COVID-19 on the LGBTQ+ North American business community.

    The recent survey by Lightspeed revealed that 16.81% of its global employees identify as LGBTQ+ and 9 out of 10 reported that they feel comfortable talking about their culture and background with their colleagues. 83% of survey respondents feel they can be their authentic selves in the workplace.

    Upcoming financial results announcement

    Lightspeed will report first-quarter 2022 financial results before the market open on Thursday, August 5th, 2021. Management will host a conference call and webcast to discuss the Company’s financial results at 8:00 am ET on Thursday, August 5th, 2021.

    Update about Acquisition of NuORDER

    On July 2, 2021, Lightspeed closed the previously reported acquisition of NuORDER. Lightspeed finalized the acquisition for cash consideration of approximately $206.9 million, net of cash acquired, and the issuance of 2,143,393 subordinate voting shares in the capital of Lightspeed at closing. An additional 500,629 subordinate voting shares in the capital of Lightspeed will be issued to certain NuORDER employees over the next three years, depending on the achievement of certain milestones.

    Ascent360 integration with Lightspeed app

    On June 24, 2021, Ascent360 integrated with Lightspeed in the app store that will bring point-of-sale and e-commerce data to life. The power of these combined solutions will allow retailers to ingest critical customer data, segment customers, and send personalized omnichannel messages that help engage and retain shoppers.

    The data that companies are already collecting can be ingested and cleansed to create a clearer view of customer behavior by combining a unique suite of tools.

    Conclusion

    There is no recent news or development about LSPD which could be the reason behind its gains in the after-market on Monday. We hope that it will continue its positive momentum in the coming days.

  • Here is why Ramaco Resources Inc. (METC) stock performed well on Monday?

    Here is why Ramaco Resources Inc. (METC) stock performed well on Monday?

    Ramaco Resources Inc. (METC) shares gained 12.12% in after-hours on Monday, July 19, 2021, and closed at $6.20 per share. Earlier in the morning session of Monday, METC’s stock lost -2.64% to close Monday’s morning session at $5.53. METC shares have risen 142.54% over the last 12 months, and they have moved down 7.83% in the past week. Over the past three months, the stock has gained 36.54%, while over the past six months, it has shed 74.45%.

    Insurance claim awarded to METC against Chubb

    On July 19, 2021, Ramaco Resources Inc announced that it was prevailed and was awarded an approximately $32.7 million jury verdict in its lawsuit against insurance companies indirectly owned by Chubb INA Holdings, Inc on July 15 and 16, 2021. The claim was filed in the United States District Court for the Southern District of West Virginia. It arose from Chubb’s denial of insurance coverage of damages incurred by the Company from the collapse of a coal storage silo, which occurred at the Company’s Elk Creek coal complex in West Virginia on November 5, 2018.

    Completion of Senior Unsecured Notes Offering

    On July 13, 2021, Ramaco Resources, Inc closed its previously announced public offering of senior unsecured notes due 2026. Due to strong demand, the size of the Offering has been increased from the previously announced $25.0 million aggregate principal amount to $30.0 million aggregate principal number of Notes.

    The Notes will mature on July 30, 2026, unless redeemed before maturity.

    New VP for Metallurgical Sales

    On May 18, 2021, Ramaco Resources, Inc appointed Bruce A. Hartshorn as Vice President, Metallurgical Sales of Ramaco Coal Sales, LLC.

    Mr. Hartshorn has more than four decades of coal sales and marketing experience, as well as an extensive background in logistics, coal purchasing and trading, and production and development. he has spent the past four years as a consultant to companies in the U.S. metallurgical coal industry, before joining Ramaco.

    Recent financial results announcement

    On May 12, 2021, Ramaco Resources, Inc announced its financial results for the first quarter of 2021 which ended on March 31, 2021.

    Q1 2021 financial highlights

    • Ramaco Resources sales were 422,000 tons in Q1 2021 compared to 416,000 tons in Q1 2020.
    • The company reported a net income of $4.1 million, or $0.10per diluted share in Q1 2021 compared to a net income of $2.0 million or $0.05 per diluted share in Q1 2020.
    • Capital expenditures were $3.7 million inQ1 2021 compared to $4.2 million for the fourth quarter of 2020.
    • The Company had liquidity of $19.2 million, consisting of $5.5 million of cash on hand plus $13.6 million of availability under its revolving credit facility as of March 31, 2021.

    Conclusion

    METC stock performed well after the company won an insurance claim against Chubb which brought more financial stability to the company. It can further surge in the coming days based on its recent developments.

  • Why did NeuroBo Pharmaceuticals Inc. (NRBO) stock surge on Monday?

    Why did NeuroBo Pharmaceuticals Inc. (NRBO) stock surge on Monday?

    NeuroBo Pharmaceuticals Inc. (NRBO) shares surged 41.49% in after-hours on Monday, July 19, 2021, and closed at $3.99 per share. Earlier in the morning session, NRBO’s stock gained 3.30% to close Monday’s session at $2.82 per share. NRBO shares have fallen 67.47% over the last 12 months, and they have moved down 3.75% in the past week. Over the past three months, the stock has lost 9.62%, while over the past six months, it has shed 53.23%.

    New Board members elected

    On July 12, 2021, NeuroBo Pharmaceuticals, Inc announced the results of the elections conducted at its Annual Meeting of Shareholders, which was held on Friday, July 9, 2021, during which Hyung Heon Kim and Andrew I. Koven were elected to the Company’s Board of Directors.

    The NeuroBo Board now consists of seven directors, six of whom are considered independent directors.

    Recent financial results announcement

    On May 17, 2021, NeuroBo Pharmaceuticals, Inc reported its financial results for the first quarter ended March 31, 2021.

    Q1 2021 financial highlights

    • In Q1 2021, Research and development expenses were approximately $1.1million compared with approximately $2.2 million in Q1 2020.
    • General and administrative expenses were $2.2 million in Q1 2021 compared to $2.6 million in Q1 2020.
    • The company suffered a net loss of $3.3 million, or $0.15per basic and diluted share in Q1 2021 compared to a net loss of $4.8 million, or $0.30 per basic and diluted share in Q1 2020.
    • As of March 31, 2021, the company had cash and cash equivalents of $13.0 million compared with $10.1 million as of December 31, 2020.

    FY 2020 financial results announcement

    On April 15, 2021, NeuroBo Pharmaceuticals, Inc announced financial results for the year ended December 31, 2020.

    FY2020 financial highlights

    • Research and Development expenses were approximately $4.5 million for the year ended December 31, 2020, as compared to approximately $5.3 million for the year ended December 31, 2019.
    • In FY 2020, general and administrative expenses were $7.8 million compared to $2.7 million for the year ended December 31, 2019.
    • The company reported a net loss of $29.7 million, or $1.83per basic and diluted share in FY 2020 compared to a net loss of $21.3 million, or $4.08 per basic and diluted share in FY 2019.
    • As of December 31, 2020, NeuroBo Pharmaceuticals had cash and cash equivalents of $10.1 million compared with $13.9 million as of December 31, 2019.

    Conclusion

    Well, as of this writing, we have no recent news or development which could be the reason behind its exceptional performance on Monday. In the absence of any current news, it is difficult for us to predict its performance in the coming days.

  • Here is why Ardelyx Inc. (ARDX) stock plummeted on Monday?

    Here is why Ardelyx Inc. (ARDX) stock plummeted on Monday?

    Ardelyx Inc. (ARDX) shares plunged 72.34% in after-hours on Monday, July 19, 2021, and closed the day at $2.13. Earlier in the morning session, ARDX’s stock gained 2.67% to close Monday’s session at $7.70. ARDX shares have risen 13.07% over the last 12 months, and they have moved down 3.87% in the past week. Over the past three months, the stock has lost 12.55%, while over the past six months, it has shed 12.90%.

    FDA found deficiencies in NDA for Tenapanor

    Ardelyx, Inc received a letter from the U.S. Food and Drug Administration on July 13, 2021, stating that, as part of its ongoing review of the company’s New Drug Application for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis, the FDA has identified deficiencies that preclude discussion of labelling and post-marketing requirements/commitments at this time. The company immediately requested a meeting to discuss the deficiencies and was notified by the FDA today that the request for a meeting was denied. The company broke this news yesterday, July 19, 2021.

    Ardelyx facing legal battles after FDA setback

    After the FDA letter, Ardelyx has to face legal actions, soon after the news on July 19, 2021, Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, announced that it is investigating potential securities violations and breach of fiduciary duty claims against Ardelyx, Inc.

    Participation in the recent conferences

    Ardelyx, Inc recently did two presentations at new tenapanor data at the European Renal Association, European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress 2021, which took place on June 5-8, 2021.

    The company also participated in a fireside chat at the Jefferies Virtual Healthcare Conference which was held on Tuesday, June 1, 2021.

    Recent financial results announcement

    On May 6, 2021, Ardelyx, Inc announced its financial results for the first quarter ended March 31, 2021.

    Q1 2021 financial highlights

    • Ardelyx reported revenue of $6.6 million in Q1 2021 compared to $1.2 million in Q1 2020.
    • In Q1 2021, research and development expenses were $20.5 million compared to $15.8 million in Q1 2020.
    • General and administrative expenses were $17.1 million in Q1 2021 compared to $7.1 million in Q1 2020.
    • The company suffered a net loss of 2 million in Q1 2021, as compared to $22.4 million for the quarter ended March 31, 2020.
    • Ardelyx had total cash, cash equivalents, and short-term investments of $178.2 million on March 31, 2021, compared to $188.6 million as of December 31, 2021.

    Conclusion

    The ARDX stock hit rock bottom on Monday after the company broke the negative outcome about its NDA for Tenapanor. ARDX stock can further go down in the coming days because it was a massive setback for the company and the company needs to address the issues as soon as possible to stop its decline in the stock market.

  • Here is why Brickell Biotech Inc. (BBI) stock faced the headwinds on the first day of the week?

    Here is why Brickell Biotech Inc. (BBI) stock faced the headwinds on the first day of the week?

    Brickell Biotech Inc. (BBI) shares fell 13.14% in after-hours on Monday, July 19, 2021, and closed Monday’s trading at $0.64. Earlier in the morning session, BBI’s stock lost 1.77% to close Monday’s session at $0.74. BBI shares have fallen 18.49% over the last 12 months, and they have moved down 10.16% in the past week. Over the past three months, the stock has lost 12.31%, while over the past six months, it has shed 33.03%. Further, the company has a current market of $51.08 million and its outstanding shares stood at 67.18 million.

    Let’s see is there any recent news or development behind its negative start on Monday?

    Increasing Bought Deal Offering of Common Stock

    On July 19, 2021, Brickell Biotech, Inc announced that the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 11,290,323 shares of common stock of the Company at a price to the public of $0.62 per share, less underwriting discounts and commissions, due to demand. The offer will close on July 22, 2021.

    Participation in the recent investor conference

    Brickell Biotech recently participated in one-on-one investor meetings at the William Blair Biotech Focus Conference 2021, which was held virtually on July 14 – 15, 2021.

    Update about patient enrollment in Phase 3 pivotal Cardigan I &II study

    On June 29, 2021, Brickell Biotech, Inc announced that the final patient has completed the Phase 3 pivotal Cardigan I study and that all planned patients have been enrolled in the Phase 3 pivotal Cardigan II study. Both studies are evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis.

    Brickell’s U.S. Phase 3 clinical program for sofpironium bromide gel, 15% is comprised of two pivotal clinical studies, Cardigan I and Cardigan II. Each study has enrolled approximately 350 subjects nine years of age and older with primary axillary hyperhidrosis.

    Initiation of Phase 1 clinical study of sofpironium bromide gel in Japan

    On June 24, 2021, the development partner of Brickell Biotech, Kaken Pharmaceutical Co., Ltd initiated a Phase 1 clinical study to assess the pharmacokinetics (PK) of sofpironium bromide gel in patients with primary palmoplantar hyperhidrosis (PPH) in Japan.

    Publication of Phase 3 Results for ECCLOCKin the Journal of Dermatology

    On June 01, 2021, Brickell Biotech, Inc announced that the results from the Phase 3 long-term safety and efficacy study conducted in Japan by its development partner, Kaken Pharmaceutical Co., Ltd were published in the peer-reviewed Journal of Dermatology1.

    Conclusion

    The BBI stock faced negativity on Monday after it announced to increase in the size of the previously announced public offering. BBI stock can further slide down in the coming days.

  • Why Aspen Group Inc. (ASPU) stock price fluctuated on Friday?

    Why Aspen Group Inc. (ASPU) stock price fluctuated on Friday?

    Aspen Group Inc. (ASPU) shares gained 6.78% in after-hours on Friday, July 16, 2021, and closed the weekly trading at $6.30 per share. Earlier in the morning session, ASPU’s stock lost 0.51% to close Friday’s session at $5.90. ASPU shares have fallen 38.09% over the last 12 months, and they have moved down 8.95% in the past week. Over the past three months, the stock has gained 11.32%, while over the past six months, it has declined 40.70%.

    Let’s have a look at its recent news and developments.

    Change to Its Board of Directors

    On July 14, 2021, Aspen Group, Inc announced the resignation of C. James Jensen from its Board of Directors. Mr. Jensen is starting a new business that will occupy most of his time and agreed to join AGI’s Advisory Board. The Company appointed Dr. Joan Prince to its Board of Directors as an independent director.

    Q4 and FY 2021 financial results announcement

    On July 13, 2021, Aspen Group, Inc released its financial results for the fourth quarter and fiscal year ended April 30, 2021.

    Q4 2021 financial highlights

    • Aspen Group reported revenue of $19.1 million for Q4 2021 compared to $14.1 million in Q4 2020.
    • In Q4 2021, GAAP gross profit was $9.9 million compared to $8.4 million inQ4 2020.
    • Operating loss was $ 2.3 million in Q4 2021 compared with an operating loss of $0.3 million in Q4 2020.
    • The company reported a net loss of $2.3 million or loss per share of $0.09 in Q4 2021 compared to a $0.7 million net loss or loss per share of $0.03in Q4 2020.
    • Adjusted EBITDA was $0.6 million in Q4 2021 compared to $1.4 million in Q4 2020.

    FY 2021 financial highlights

    • Aspen Group reported revenue of $67.8 million for FY 2021 compared to $49.1 million in FY 2020.
    • GAAP gross profit was $36.9 million in FY 2021 compared to $28.9 million in FY 2020.
    • The operating loss was $ 8.2 million in FY 2021 compared with an operating loss of $4.0 million in FY 2020.
    • The company reported a net loss of $10.4 million or loss per share of $0.44 in FY 2021 compared to a $5.7 million net loss or loss per share of $0.29 in FY 2020.
    • Adjusted EBITDA was $1.3 million in FY 2021 compared to $2.7 million in FY 2020.

    The financial outlook for FY 2022

    For FY 2020, the company is expecting

    • Revenue to be in the range of $85.0 million to $88.0 million.
    • Net income(loss) to be between $4.5 million to $3.0 million
    • GAAP earnings (loss) per share in the range of $0.18 to $0.12
    • Adjusted EBITDA in the range of $2.0 million to$4.0 million

    Conclusion

    ASPU stock minor loss and later after-hour gains on Friday has no ground. As of this writing, we were unable to find any recent news or development. We hope that ASPN will continue to perform well on Monday as well.

  • Why did Washington Real Estate Investment Trust (WRE) stock surge in the after-markets on Friday?

    Why did Washington Real Estate Investment Trust (WRE) stock surge in the after-markets on Friday?

    Washington Real Estate Investment Trust (WRE) shares went up 8.48% in after-hours on Friday, July 16, 2021, and closed the weekly trading at $26.74 per share. Earlier in the morning session, WRE’s stock lost 0.36% to close Friday’s session at $24.65 per share. WRE shares have risen 13.28% over the last 12 months, and they have moved up 0.94% in the past week. Over the past three months, the stock has gained 7.03%, while over the past six months, it has declined 8.88%.

    Upcoming financial results announcement

    Washington Real Estate Investment Trust will release second-quarter earnings results after market close on Thursday, July 29, 2021.

    What is expected for Q2 2021?

    the company provided a financial outlook for Q2 2021 when it announced its Q1 2021 financial results.

    For Q2 2021, the company is expecting

    • Net loss per diluted share to be in the range of $0.03 to 0.00 $per share.
    • Real estate depreciation and amortization of $0.35
    • NAREIT FFO in the range of $0.32 to $0.35 per diluted share
    • Core FFO in the range of $0.32 to $0.35 per diluted share

    Q1 2021 financial results announcement

    On April 28, 2021, Washington Real Estate Investment Trust announced its financial results for the quarter ended March 31, 2021.

    Q1 2021 financial highlights

    • Washington Real Estate Investment Trust reported revenue of $69.63 million in Q1 2021 compared to $76.79 million in Q1 2020.
    • Total operating expenses were $61.94 million in Q1 2021 compared to $64.7 million inQ1 2020.
    • The company suffered a net loss of $1.1 million or $0.02 per diluted share in Q1 2021 compared to a net loss of $1.71 million or $0.02 per diluted share in Q1 2020.

    Dividend declaration

    On April 5, 2021, the Board of Trustees of WashREIT announced a quarterly dividend of $0.30 per share to be paid on July 6, 2021, to shareholders of record on June 23, 2021.

    $350 Million of Green Bonds expansion

    On April 21, 2021, WashREIT announced an expansion of its Green Bond Framework for eligible green projects, including eight multifamily assets acquired in 2019. As outlined in WashREIT’s Green Bond Framework, WashREIT intends to achieve BREEAM In-Use Very Good certifications for the majority of these assets.

    Conclusion

    There is no recent news or development about WRE at the moment which could be linked with its Friday’s performance. We hope that it will continue to perform well on Monday as well.